Kilitch Drugs (India) Ltd (KILITCH) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jenburkt Pharma

Wanbury

Medicamen Biotec

Kilitch Drugs

Kopran

Shree Ganesh Rem

Themis Medicare

Bharat Parenter.

Anlon Healthcare

Solara Active PP

Influx Health.

Why is Kilitch Drugs (India) Ltd ?

Poor Management Efficiency with a low ROE of 7.61%

The company has been able to generate a Return on Equity (avg) of 7.61% signifying low profitability per unit of shareholders funds

Flat results in Sep 25

PBT LESS OI(Q) At Rs 2.74 cr has Fallen at -55.7% (vs previous 4Q average)
INTEREST(9M) At Rs 4.57 cr has Grown at 32.85%
DEBT-EQUITY RATIO(HY) Highest at 0.32 times

Despite the size of the company, domestic mutual funds hold only 0% of the company

Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kilitch Drugs for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Kilitch Drugs

7.11%

0.16

43.62%

Sensex

8.49%

0.74

11.41%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

30.28%

EBIT Growth (5y)

96.35%

EBIT to Interest (avg)

4.04

Debt to EBITDA (avg)

1.83

Net Debt to Equity (avg)

-0.01

Sales to Capital Employed (avg)

0.70

Tax Ratio

25.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

10.22%

ROE (avg)

7.61%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.13

EV to EBIT

19.91

EV to EBITDA

17.80

EV to Capital Employed

2.15

EV to Sales

2.69

PEG Ratio

0.38

Dividend Yield

ROCE (Latest)

10.78%

ROE (Latest)

10.38%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

PAT(9M)

At Rs 21.62 cr has Grown at 59.56%

NET SALES(9M)

At Rs 153.29 cr has Grown at 21.91%

CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 33.10 cr

-10What is not working for the Company

PBT LESS OI(Q)

At Rs 2.74 cr has Fallen at -55.7% (vs previous 4Q average

INTEREST(9M)

At Rs 4.57 cr has Grown at 32.85%

DEBT-EQUITY RATIO(HY)

Highest at 0.32 times

NET SALES(Q)

At Rs 48.92 cr has Fallen at -5.9% (vs previous 4Q average

NON-OPERATING INCOME(Q)

is 70.85 % of Profit Before Tax (PBT

Loading Valuation Snapshot...

Here's what is working for Kilitch Drugs

Profit After Tax (PAT) - Nine Monthly

At Rs 21.62 cr has Grown at 59.56%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Cash and Cash Equivalents - Half Yearly

Highest at Rs 33.10 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Profit After Tax (PAT) - Nine Monthly

Higher at Rs 21.62 Cr

than preceding 12 month period ended Sep 2025 of Rs 19.51 cr

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Kilitch Drugs

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 2.74 cr has Fallen at -55.7% (vs previous 4Q average)

over average PBT of the previous four quarters of Rs 6.19 Cr

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Interest - Nine Monthly

At Rs 4.57 cr has Grown at 32.85%

over preceding nine months period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Net Sales - Quarterly

At Rs 48.92 cr has Fallen at -5.9% (vs previous 4Q average)

over average Net Sales of the previous four quarters of Rs 52.00 Cr

MOJO Watch

Near term sales trend is negative

Net Sales (Rs Cr)

Non Operating Income - Quarterly

is 70.85 % of Profit Before Tax (PBT)

MOJO Watch

The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Debt-Equity Ratio - Half Yearly

Highest at 0.32 times

in the last five half yearly periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Non Operating Income - Quarterly

Highest at Rs 6.66 cr

in the last five quarters

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating Income